Cargando…

Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes Over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis

Treatment-related adverse events (AEs) can obfuscate the maintenance of a conventional schedule of sunitinib in patients with metastatic renal cell carcinoma. Accordingly, alternative schedules seeking to improve the safety profile of sunitinib have been tested. Recently, two meta-analyses similarly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Doo Yong, Kang, Dong Hyuk, Kim, Jong Won, Kim, Do Kyung, Lee, Joo Yong, Hong, Chang Hee, Cho, Kang Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966535/ https://www.ncbi.nlm.nih.gov/pubmed/31766332 http://dx.doi.org/10.3390/cancers11121830

Ejemplares similares

Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis
por: Kang, Hee Jung, et al.
Publicado: (2020)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
por: Di Paolo, Antonello, et al.
Publicado: (2017)

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
por: Kleibeuker, Esther A, et al.
Publicado: (2015)

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2017)

A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Deng, Huan, et al.
Publicado: (2020)

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2018)

Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours
por: SAPONARA, MARISTELLA, et al.
Publicado: (2014)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
por: Zhu, Xudong, et al.
Publicado: (2021)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria
por: Milligan, Rachael, et al.
Publicado: (2019)

Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer
por: Winer, Arthur, et al.
Publicado: (2021)

Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma
por: Zhang, Xingming, et al.
Publicado: (2018)

VIII. Immunological Effectiveness of the Two Dose Schedule
por: Miller, David G., et al.
Publicado: (1962)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

Dose Schedule Optimization and the Pharmacokinetic Driver of Neutropenia
por: Patel, Mayankbhai, et al.
Publicado: (2014)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
por: Lin, Harrison Sicheng, et al.
Publicado: (2022)

Building an adaptive dose simulation framework to aid dose and schedule selection
por: Hooijmaijers, Richard, et al.
Publicado: (2023)

Update on LHC installations schedule
por: Weisz, S
Publicado: (2005)

Extended-schedule dose-dense temozolomide in refractory gliomas
por: Berrocal, A., et al.
Publicado: (2009)

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1996)

Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial
por: Cella, David, et al.
Publicado: (2014)

Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study
por: Abdelaziz, Lobna A., et al.
Publicado: (2021)

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
por: Allman, Kimberly D., et al.
Publicado: (2019)

New dosing schedules of dasatinib for CML and adverse event management
por: Wong, Siu-Fun
Publicado: (2009)

Dosing Schedules for Pneumococcal Conjugate Vaccine: Considerations for Policy Makers
por: Whitney, Cynthia G., et al.
Publicado: (2014)

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
por: Gatault, Philippe, et al.
Publicado: (2015)

The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules
por: Arnold, Kimberly M, et al.
Publicado: (2018)

Near-infrared photoimmunotherapy: a comparison of light dosing schedules
por: Ogata, Fusa, et al.
Publicado: (2017)

Chronotherapy of Early Colon Cancer: Advantage of Morning Dose Schedules
por: Axelrod, David E
Publicado: (2022)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis
por: Zhang, Chenli, et al.
Publicado: (2021)

Resilience in the Surgical Scheduling to Support Adaptive Scheduling System
por: Wiyartanti, Lisa, et al.
Publicado: (2020)

Visceral Adiposity as a Significant Predictor of Sunitinib-Induced Dose-Limiting Toxicities and Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma
por: Park, Jee Soo, et al.
Publicado: (2020)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2017)

Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule.
por: Evans, B. D., et al.
Publicado: (1984)

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings
por: Wilson, S, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5i5b5q3h648t0fivm7p9ugqtq2